iRNA agents with biocleavable tethers
View Patent ↗The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
1. A bio-cleavable oligonucleotide-ligand conjugate represented by the following formula:
wherein:
NA is a chemically modified or unmodified oligonucleotide;
L is a ligand selected from the group consisting of a multivalent galactose and a multivalent N-acetyl-galactosamine;
represents a tether comprising one or more linking groups having a cleavable disulfide group (—SS—), wherein each
linking group is either present or absent;
is a cyclic carrier selected from the group consisting of hydroxyproline, piperidine, morpholine, piperazine, and decalin or acyclic carrier moiety containing a serinol backbone or a diethanolamine backbone;
X is a chemical linkage between the ligand L and the tether;
Y is a chemical linkage between the tether and the
and
Z is a chemical linkage between the
and the oligonucleotide NA.
2. The bio-cleavable oligonucleotide-ligand conjugate of claim 1 , wherein the oligonucleotide NA is a double-stranded RNA (dsRNA) agent comprising a sense strand and an antisense strand, and wherein each strand has at least 21 nucleotides in length and the duplex region of the dsRNA agent is about 19 nucleotides in length.
3. The bio-cleavable oligonucleotide-ligand conjugate of claim 1 , wherein the oligonucleotide NA is a double-stranded RNA having a duplex region of about 20-21 nucleotides in length and one or two 3′ overhangs of about 2 nucleotides in length.
4. The bio-cleavable oligonucleotide-ligand conjugate of claim 1 , wherein the oligonucleotide NA is a double-stranded RNA (dsRNA) agent comprising a sense strand and an antisense strand, and wherein the ligand is attached to the sense strand.
5. The bio-cleavable oligonucleotide-ligand conjugate of claim 4 , wherein the ligand is attached to position 1, 2, or 3 of the 3′ end of the sense strand.
6. The bio-cleavable oligonucleotide-ligand conjugate of claim 1 , wherein the oligonucleotide NA is a double-stranded RNA (dsRNA) agent comprising a sense strand and an antisense strand, and wherein the ligand is attached to the antisense strand.
7. The bio-cleavable oligonucleotide-ligand conjugate of claim 6 , wherein the ligand is attached to the 3′-end of the antisense strand.
8. The bio-cleavable oligonucleotide-ligand conjugate of claim 1 , wherein each of X, Y, and Z is independently selected from the group consisting of —NHC(O)—, —C(O)NH—, —OC(O)NH—, —NHC(O)O—, —O—, —S—, —SS—, —S(O)—, —S(O 2 )—, —NHC(O)NH—, —NHC(S)NH—, —C(O)O—, —OC(O), —NHC(S)—, —NHC(S)O—, —C(S)NH—, —OC(S)NH—, —NHC(S)O—, —CH 2 —, —CH 2 CH═CH—, —C(O)CH═CH—, —NH—CH 2 CH═CH—, —O—P(O)(OH)—O—, —O—P(S)(OH)—O—, —O—P(S)(SH)—O—, —S—P(O)(OH)—O—, —O—P(O)(OH)—S, —S—P(O)(OH)—S—, —O—P(S)(OH)—S—, —S—P(S)(OH)—O—, —O—P(O)(R)—O—, —O—P(S)(R)—O—, —S—P(O)(R)—O—, —S—P(S)(R)—O—, —S—P(O)(R)—S—, and —O—P(S)(R)—S—; wherein R is alkyl, fluoroalkyl, aryl, or aralkyl.
9. The bio-cleavable oligonucleotide-ligand conjugate of claim 1 , wherein the tether is selected from the group consisting of —(CH 2 ) m —S—S—(CH 2 ) n —, (CH 2 ) m1 —(CH═CH) m2 —(CH 2 ) m3 —S—S—(CH 2 ) n1 —(CH═CH) n2 —(CH 2 ) n3 , (CH 2 ) m1 —(C≡C) m2 —(CH 2 ) m3 —S—S—(CH 2 ) n1 —(C≡C) n2 —(CH 2 ) n3 , —(CH 2 CH 2 O) m1 —(CH 2 ) m2 —S—S—(CH 2 ) n1 —(OCH 2 CH 2 ) n2 , —(CH 2 CH 2 NH) m1 —(CH 2 ) m2 —S—S—(CH 2 ) n1 —(NHCH 2 CH 2 ) n2 , and —(CH 2 ) m —S—S—(CH 2 ) n —X—(CH 2 ) p —S—S—(CH 2 ) q —; wherein each of m, m1, m2, m3, n, n1, n2, n3, p, and q is independently 0-20.
10. A bio-cleavable oligonucleotide-ligand conjugate represented by the following formula:
wherein:
NA is a chemically modified or unmodified oligonucleotide;
represents a tether comprising one or more linking groups having a cleavable disulfide group (—SS—), wherein each
linking group is either present or absent;
L is a ligand selected from the group consisting of a multivalent galactose and a multivalent N-acetyl-galactosamine;
X is a chemical linkage between the ligand L and the tether;
Z is a chemical linkage between the tether and the oligonucleotide NA;
each of X and Z is independently selected from the group consisting of —NHC(O)—, —C(O)NH—, —OC(O)NH—, —NHC(O)O—, —O—, —S—, —SS—, —S(O)—, —S(O 2 )—, —NHC(O)NH—, —NHC(S)NH—, —C(O)O—, —OC(O)—, —NHC(S)—, —NHC(S)O—, —C(S)NH—, —OC(S)NH—, —NHC(S)O—, —CH 2 —, —CH 2 CH═CH—, —C(O)CH═CH—, —NH—CH 2 CH═CH—, —O—P(O)(OH)—O—, —O—P(S)(OH)—O—, —O—P(S)(SH)—O—, —S—P(O)(OH)—O—, —O—P(O)(OH)—S, —S—P(O)(OH)—S—, —O—P(S)(OH)—S—, —S—P(S)(OH)—O—, P(S)(OH)—O—, —O—P(O)(R)—O—, —O—P(S)(R)—O—, —S—P(O)(R)—O—, —S—P(S)(R)—O—, —S—P(O)(R)—R—, and —O—P(S)(R)—S—; wherein R is alkyl, fluoroalkyl, aryl, or aralkyl; and
the tether is a cleavable linking group selected from the group consisting of —(CH 2 ) m —S—S—(CH 2 ) n —, (CH 2 ) m1 —(CH═CH) m2 —(CH 2 ) m3 —S—S—(CH 2 ) n1 —(CH═CH) n2 —(CH 2 ) n3 , (CH 2 ) m1 —(C≡C) m2 —(CH 2 ) m3 —S—S—(CH 2 ) n1 —(C≡C) n2 —(CH 2 ) n3 , —(CH 2 CH 2 O) m1 —(CH 2 ) m2 —S—S—(CH 2 ) n1 —(OCH 2 CH 2 ) n2 , —(CH 2 CH 2 NH) m1 —(CH 2 ) m2 —S—S—(CH 2 ) n1 —(NHCH 2 CH 2 ) n2 , and —(CH 2 ) m —S—S—(CH 2 ) p —S—S—(CH 2 ) q —; wherein each of m, m1, m2, m3, n, n1, n2, n3, p, and q is independently 0-20.
11. The bio-cleavable oligonucleotide-ligand conjugate of claim 10 , wherein the oligonucleotide NA is a double-stranded RNA (dsRNA) agent comprising a sense and antisense strands, wherein each strand has at least 21 nucleotides in length, and the duplex region of the dsRNA agent is about 19 nucleotides in length.
12. The bio-cleavable oligonucleotide-ligand conjugate of claim 10 , wherein the oligonucleotide NA is a double-stranded RNA having a duplex region of about 20-21 nucleotides in length and one or two 3′ overhangs of about 2 nucleotides in length.
13. The bio-cleavable oligonucleotide-ligand conjugate of claim 10 , wherein the oligonucleotide NA is a double-stranded RNA (dsRNA) agent comprising a sense strand and an antisense strand, and wherein the ligand is attached to the sense strand.
14. The bio-cleavable oligonucleotide-ligand conjugate of claim 10 , wherein the oligonucleotide NA is a double-stranded RNA (dsRNA) agent comprising a sense strand and an antisense strand, and wherein the ligand is attached to position 1, 2, or 3 of the 3′ end of the sense strand.
15. The bio-cleavable oligonucleotide-ligand conjugate of claim 10 , wherein the oligonucleotide NA is a double-stranded RNA (dsRNA) agent comprising a sense strand and an antisense strand, and wherein the ligand is attached to the antisense strand.
16. The bio-cleavable oligonucleotide-ligand conjugate of claim 15 , wherein the ligand is attached to the 3′-end of the antisense strand.